Lantheus (0L8) Stock Price & Analysis
0L8 Stock Chart & Stats
- Day’s Range
- EUR 89.60 - EUR 89.70
- 52-Week Range
- EUR 43.37 - EUR 99.00
- Previous Close
- EUR 89.90
- Volume
- N/A
- Average Volume (3M)
- 138
- Market Cap
- EUR 5.87B
- Enterprise Value
- EUR 7.52B
- Total Cash (Recent Filing)
- EUR 593.30M
- Total Debt (Recent Filing)
- EUR 624.96M
- Price to Earnings (P/E)
- 23.8
- Beta
- 0.07
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Robust operating and free cash flow indicates that Lantheus converts its business activity into funding reliably. This supports investment in radiopharmaceutical capacity, commercial expansion, and strategic initiatives while reducing dependence on external financing over the next several quarters.
Revenue Re-acceleration And Healthy Margins
The sharp revenue re-acceleration, combined with strong gross and operating margins, suggests meaningful demand and operating leverage across Lantheus’ portfolio. If maintained, this performance can strengthen earnings capacity and provide resources to expand key imaging franchises.
Shareholder Approval Supports Strategic Combination
Shareholder approval removes a major corporate hurdle and supports Curium’s plan to combine Lantheus’ radiodiagnostics platform with broader radiopharmaceutical capabilities. The transaction could improve strategic scale and commercial reach, subject to remaining regulatory and closing conditions.
Bears Say
Bottom-line Earnings Volatility
Declining net income despite healthy gross and operating margins indicates pressure below the operating line and less consistent bottom-line performance. This volatility can complicate planning, reduce confidence in near-term earnings conversion, and limit the predictability of shareholder returns.
Moderate Debt Remains On Balance Sheet
Leverage has improved substantially, but the remaining debt burden means Lantheus is not operating from a net-cash position. Interest obligations and refinancing needs could reduce flexibility for investment or strategic execution if profitability weakens over the next several quarters.
Merger Remains Exposed To Regulatory And CVR Execution Risk
The ownership transition still depends on antitrust approval and other closing conditions, creating execution uncertainty despite shareholder support. In addition, milestone-based CVR value depends on future commercial performance, so the transaction’s full economic benefit is not assured.
Lantheus News
0L8 FAQ
What was Lantheus’s price range in the past 12 months?
What is Lantheus’s market cap?
When is Lantheus’s upcoming earnings report date?
How were Lantheus’s earnings last quarter?
Is Lantheus overvalued?
Does Lantheus pay dividends?
What is Lantheus’s EPS estimate?
How many shares outstanding does Lantheus have?
What happened to Lantheus’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lantheus?
What is the TipRanks Smart Score and how is it calculated?
Lantheus Stock Smart Score
Company Description
Lantheus
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mary Anne Heino
- Employees
- 1,193
- Website
- www.lantheus.com
- Address
- 201 Burlington Road, Bedford, MA, 01730, US
Lantheus (0L8) Earnings & Revenues
0L8 Earnings Call
Earnings Call SentimentNeutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.
View all DE:0L8 earnings summaries0L8 Net sales Breakdown
- 65.91% Radiopharmaceutical oncology
- 30.09% Precision diagnostics
- 4.00% Strategic Partnerships and other revenue
0L8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 10 | 0 | 2 |











